Brad Hively Sells 13,333 Shares of Oncology Institute (NASDAQ:TOI) Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Brad Hively sold 13,333 shares of Oncology Institute stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $3.77, for a total value of $50,265.41. Following the completion of the transaction, the director owned 683,721 shares in the company, valued at $2,577,628.17. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Oncology Institute Stock Performance

Shares of Oncology Institute stock traded up $0.07 during trading hours on Tuesday, hitting $3.84. 1,161,850 shares of the company were exchanged, compared to its average volume of 1,698,535. The company has a current ratio of 1.68, a quick ratio of 1.39 and a debt-to-equity ratio of 14.58. The business has a 50-day moving average of $3.74 and a 200-day moving average of $3.40. The Oncology Institute, Inc. has a 1 year low of $0.17 and a 1 year high of $4.88. The stock has a market capitalization of $377.78 million, a price-to-earnings ratio of -6.00 and a beta of 0.17.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The firm had revenue of $136.56 million during the quarter, compared to analyst estimates of $122.63 million. Oncology Institute had a negative net margin of 13.21% and a negative return on equity of 1,527.21%.

Analyst Ratings Changes

Several research analysts recently issued reports on TOI shares. Needham & Company LLC assumed coverage on shares of Oncology Institute in a report on Tuesday, November 25th. They set a “buy” rating and a $5.00 price target for the company. BTIG Research reiterated a “buy” rating and set a $7.00 target price on shares of Oncology Institute in a research report on Tuesday, October 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.50.

Institutional Trading of Oncology Institute

A number of institutional investors have recently added to or reduced their stakes in the stock. Prelude Capital Management LLC acquired a new position in Oncology Institute during the third quarter worth about $41,000. ProShare Advisors LLC purchased a new stake in shares of Oncology Institute during the 2nd quarter worth approximately $25,000. BNP Paribas Financial Markets grew its holdings in shares of Oncology Institute by 141.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock worth $42,000 after acquiring an additional 7,091 shares during the period. Sherbrooke Park Advisers LLC purchased a new position in Oncology Institute in the 3rd quarter valued at approximately $51,000. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in Oncology Institute in the 2nd quarter valued at approximately $32,000. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.